Liver cancer screening in high-risk populations.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2016-01-01 Epub Date: 2015-11-30 DOI:10.2217/hep.15.35

Morris Sherman

引用次数: 1

Abstract

Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.

查看原文本刊更多论文

高危人群的肝癌筛查

肝脏疾病患者有发生肝细胞癌(HCC)的风险，但不同疾病之间的风险不同，并且根据其他几个变量(如年龄、潜在肝脏疾病类型和疾病严重程度)也有所不同。一些风险评分已经被开发出来，以更充分地量化个体患者的HCC风险。每个风险评分适用于特定人群(慢性乙型或丙型肝炎，移植名单上的患者，一般的肝硬化，等等)。大多数关于风险评分的出版物都没有提供明确的指导，说明测量的风险达到何种程度才足以引发监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.